Aquestive Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AQST and other ETFs, options, and stocks.

About AQST

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. 

CEO
Daniel Barber
CEODaniel Barber
Employees
147
Employees147
Headquarters
Warren, New Jersey
HeadquartersWarren, New Jersey
Founded
2004
Founded2004
Employees
147
Employees147

AQST Key Statistics

Market cap
522.96M
Market cap522.96M
Price-Earnings ratio
-5.43
Price-Earnings ratio-5.43
Dividend yield
Dividend yield
Average volume
2.61M
Average volume2.61M
High today
$4.31
High today$4.31
Low today
$4.06
Low today$4.06
Open price
$4.10
Open price$4.10
Volume
1.37M
Volume1.37M
52 Week high
$7.55
52 Week high$7.55
52 Week low
$2.12
52 Week low$2.12

Stock Snapshot

The current Aquestive Therapeutics(AQST) stock price is $4.29, with a market capitalization of 522.96M. The stock trades at a price-to-earnings (P/E) ratio of -5.43.

As of 2026-03-09, Aquestive Therapeutics(AQST) stock has fluctuated between $4.06 and $4.31. The current price stands at $4.29, placing the stock +5.5% above today's low and -0.6% off the high.

Aquestive Therapeutics(AQST) shares are trading with a volume of 1.37M, against a daily average of 2.61M.

During the past year, Aquestive Therapeutics(AQST) stock moved between $2.12 at its lowest and $7.55 at its peak.

During the past year, Aquestive Therapeutics(AQST) stock moved between $2.12 at its lowest and $7.55 at its peak.

AQST News

TipRanks 4d
AI Execution Risks Threaten Aquestive Therapeutics’ Competitiveness and Profitability

Aquestive Therapeutics, Inc. (AQST) has disclosed a new risk, in the Innovation / R&D category. Aquestive Therapeutics, Inc. faces a competitive threat if it l...

TipRanks 5d
Aquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook

The latest announcement is out from Aquestive Therapeutics ( (AQST) ). On March 3, 2026, Aquestive Therapeutics amended its existing revenue-sharing Purchase a...

TipRanks 5d
Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)

Reports Q4 revenue $13.02M, consensus $13.28M. “We are well-positioned in 2026 to advance Anaphylm, the first and only oral epinephrine rescue medication, towar...

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own AQST. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.